REG - Immupharma PLC - Result of Retail Offer and Director Shareholding

ImmuPharmaAnnouncement

07/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230907:nRSG6396La&default-theme=true

RNS Number : 6396L  Immupharma PLC  07 September 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND,
CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER
JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE
A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

7 September 2023

 

ImmuPharma Plc

 

("ImmuPharma" or the "Company")

 

Result of Retail Offer and Director Shareholding

 

ImmuPharma Plc is pleased to announce that further to the Company's
announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally
raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary
Shares at a price of 2 pence to existing retail investors of the Company, via
the Winterflood Retail Access Platform ("WRAP"), in addition to the £1.35
million raised in the Subscription and Direct Subscription.

 

An application has been made to the London Stock Exchange for the 6,534,150
new Ordinary Shares to be admitted to trading on AIM. Admission is expected to
take place, and dealings on AIM in the Retail Offer Shares are expected to
commence, at 8.00 a.m. on or around 12 September 2023.

 

Director Dealing

 

Lisa Baderoon, Director, subscribed for 1,000,000 Retail Offer Shares in the
Retail Offer. Following Admission, Lisa Baderoon's shareholding will be
1,583,963 Ordinary Shares comprising 0.38% of the issued share capital.]

 

Total Voting Rights

 

Following Admission, the Company will have 416,437,265 Ordinary Shares in
issue. Since the Company currently holds no shares in treasury, the total
number of voting rights in the Company will therefore be 416,437,265. These
figures may therefore be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement have the same
meanings as set out in the announcement of the Company at 7:02 a.m. on 31
August 2023.

 

 

For Further Information

 

 ImmuPharma plc
 Tim McCarthy, Chief Executive Officer       +44 (0) 207 206 2650

 Lisa Baderoon, Head of Investor Relations   + 44 (0) 7721 413496

   Stanford Capital Partners
 Patrick Claridge                            +44 (0) 203 650 3650

 Bob Pountney

 SPARK Advisory Partners Limited             +44 (0) 203 368 3554
 Neil Baldwin                                +44 (0) 113 370 8974

 Winterflood Retail Access Platform          WRAP@winterflood.com
 Alex Skrine, Head of Electronic Trading     +44 (0) 20 3100 0000
 Phoebe Pankhurst, Corporate Finance

 Haris Khawaja, Corporate Finance

 

 

 

Further information on the Company can be found on its website at
https://www.immupharma.co.uk/

 

The Company's LEI is 213800VZKGHXC7VUS895

 

 1   Details  of  the  person  discharging  managerial  responsibilities  /  person  closely
     associated
 a)  Name                                                                                             Lisa Baderoon
 2   Reason for notification
 a)  Position / status                                                                                Director
 b)  Initial notification                                                                             Initial

     /Amendment
 3   Details of the issuer,  emission allowance market participant, auction platform,
     auctioneer or auction monitor
 a)  Name                                                                                             ImmuPharma Plc
 b)  LEI                                                                                              213800VZKGHXC7VUS895
 4   Details of the transaction(s):
     section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument                                      Ordinary shares of 1p (£0.01) each in the capital of ImmuPharma plc

     Identification code                                                                              ISIN GB0033711010

     Nature of the transaction                                                                        Subscription in retail offer
     Price(s) and volumes(s)                                                                          Price(s)  Volume(s)
                                                                                                      £0.02     1,000,000

 

 d)  Aggregated information

     -           Aggregated volume                                                                    1,000,000

     -              Aggregated price                                                                  £0.02
 e)  Date of the transaction                                                                          7 September 2023
 f)  Place of the transaction                                                                         Outside a trading venue

 

 

d)

Aggregated information

-           Aggregated volume

-              Aggregated price

 

1,000,000

£0.02

e)

Date of the transaction

7 September 2023

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKABNDBKBCCK